Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Jim Bishop who wrote (68213)	10/24/2000 2:06:01 AM
From: asker2	Read Replies (1) \| Respond to of 150070

Thanks Jim...I did notice that you don't post there much anymore...after seeing all the different links that you post from all kinds of places... I don't see where you have time to sleep :>) ....which is exactly what I'm about to do... g'nite...

To: Jim Bishop who wrote (68213)	10/24/2000 7:40:46 AM
From: TomNY	Read Replies (4) \| Respond to of 150070

Big DNAP news this morning! ( BW)(FL-DNAPRINT/ORCHID)(DNAP)(ORCH) DNAPrint and Orchid Announce Option Agreement Business Editors SARASOTA, Fla. and PRINCETON, N.J.--(BUSINESS WIRE)--Oct. 24, 2000--DNAPrint genomics, Inc. (Pink Sheets:DNAP) and Orchid BioSciences, Inc. (Nasdaq:ORCH) today announced that Orchid has purchased an option to co-develop and co-commercialize certain existing and future intellectual properties and products of DNAPrint genomics. Under the terms of the agreement, DNAPrint grants Orchid an option to license the rights to co-develop and/or co-commercialize certain DNAPrint genomics products and properties. The option provides Orchid exclusive rights to negotiate partnership terms with DNAPrint for these products and properties. The option covers a broad spectrum of intellectual properties, for example genetic algorithms, software and information resources such as single nucleotide polymorphism (SNP) and haplotype determinations and multivariate associations with complex human traits and diseases. Other terms of the agreement were not disclosed. "Partnering with a company like Orchid highlights the potential value and innovative nature of the scientific approach and products of DNAPrint genomics. It could provide us with an established channel for distribution of our intellectual properties and products, and as such, this new relationship represents the accomplishment of an important milestone for DNAPrint genomics," said Tony Frudakis, Ph.D., president of DNAPrint. "By partnering with an established genomics player, we can leverage their expertise and established infrastructure to realize the commercial value of our products. This option may also enable us to focus on our scientific strengths in diagnomics product development and on expanding the number and types of applied genomics products we may be able to produce in the future." "We are very pleased to have the potential opportunity to partner with DNAPrint genomics," said Russell Granzow, vice president of marketing, sales and business development of Orchid. "DNAPrint's innovative work in algorithms, software and other knowledge resources are designed to improve the clinical utility of genetics and pharmacogenetics data and research." DNAPrint genomics, Inc. is developing complex genetic analytics and information resources for next generation personalized medicine. The company's products will provide practitioners of genomic research and personalized medicine with a comprehensive system for complex trait dissection and patient classification. DNAPrint genomics Inc. was founded by a group of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. On October 17th, the Company announced that it merged with a SEC 12g full reporting company, and expects to be trading on the OTC Bulletin Board within 30 days. For more information about the company, please visit www.DNAPrint.com All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. Orchid BioSciences, Inc. is a leading provider of products, services and technologies for SNP scoring and genetic diversity analyses. Orchid has developed SNP-IT(TM), its proprietary SNP analysis technology, and markets SNPstream(TM) instruments and SNPware(TM) consumables that rapidly generate highly accurate, cost effective SNP information. SNP-IT is usable in environments ranging from small-scale laboratories to large commercial facilities. Its versatility also enables Orchid to partner with industry leaders to make SNP-IT-enabled products available on a wide variety of instrument platforms. Orchid also provides high throughput SNP scoring services to pharmaceutical, agricultural and academic customers through its MegaSNPatron(TM) facility, and DNA testing through its GeneScreen facilities that conduct paternity, forensics and transplantation testing. Through its Pharmaceutical Value Creation strategy, Orchid also seeks to identify proprietary medical applications of SNPs. More information on Orchid can be found at its Web site www.orchid.com.